全文获取类型
收费全文 | 222495篇 |
免费 | 18894篇 |
国内免费 | 4703篇 |
专业分类
耳鼻咽喉 | 3346篇 |
儿科学 | 4161篇 |
妇产科学 | 3800篇 |
基础医学 | 16969篇 |
口腔科学 | 7283篇 |
临床医学 | 21168篇 |
内科学 | 20355篇 |
皮肤病学 | 2428篇 |
神经病学 | 10807篇 |
特种医学 | 5882篇 |
外国民族医学 | 13篇 |
外科学 | 24110篇 |
综合类 | 36566篇 |
现状与发展 | 10篇 |
一般理论 | 24篇 |
预防医学 | 29012篇 |
眼科学 | 2035篇 |
药学 | 22140篇 |
363篇 | |
中国医学 | 26403篇 |
肿瘤学 | 9217篇 |
出版年
2024年 | 986篇 |
2023年 | 4370篇 |
2022年 | 8227篇 |
2021年 | 10792篇 |
2020年 | 10524篇 |
2019年 | 11770篇 |
2018年 | 10396篇 |
2017年 | 9062篇 |
2016年 | 8123篇 |
2015年 | 7584篇 |
2014年 | 15023篇 |
2013年 | 15223篇 |
2012年 | 13453篇 |
2011年 | 14459篇 |
2010年 | 11577篇 |
2009年 | 10004篇 |
2008年 | 9377篇 |
2007年 | 9402篇 |
2006年 | 8067篇 |
2005年 | 6830篇 |
2004年 | 5619篇 |
2003年 | 5028篇 |
2002年 | 3907篇 |
2001年 | 3248篇 |
2000年 | 2858篇 |
1999年 | 2320篇 |
1998年 | 1880篇 |
1997年 | 1706篇 |
1996年 | 1367篇 |
1995年 | 1353篇 |
1994年 | 1200篇 |
1993年 | 1068篇 |
1992年 | 979篇 |
1991年 | 884篇 |
1990年 | 792篇 |
1989年 | 765篇 |
1988年 | 689篇 |
1987年 | 655篇 |
1986年 | 602篇 |
1985年 | 1870篇 |
1984年 | 2130篇 |
1983年 | 1341篇 |
1982年 | 1774篇 |
1981年 | 1224篇 |
1980年 | 1043篇 |
1979年 | 919篇 |
1978年 | 750篇 |
1977年 | 562篇 |
1976年 | 701篇 |
1975年 | 482篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
Liza Johannesson Anji Wall Andreas Tzakis Cristiano Quintini Elliott G. Richards Kathleen O’Neill Paige M. Porrett Giuliano Testa 《American journal of transplantation》2021,21(5):1699-1704
The parallel emergence of uterus transplantation (UTx) and other transplantation innovations including face and hand transplantation led to the categorization of the uterus as a vascular composite allograft (VCA). With >60 transplants and >20 births worldwide, UTx is transitioning rapidly from a research endeavor to an effective treatment option for women with uterine factor infertility. While it originally made sense to group the innovations under one umbrella, it is time to revisit the designation of UTx as a VCA. We describe how UTx needs unique policy, procedural codes, insurance contracts, and educational initiatives. We contend that separating UTx from VCAs may become necessary in the future to avoid hindering the growth and regulation of this field. 相似文献
993.
Emilio D. Poggio Joshua J. Augustine Susana Arrigain Daniel C. Brennan Jesse D. Schold 《American journal of transplantation》2021,21(8):2824-2832
Current short-term kidney post–transplant survival rates are excellent, but longer-term outcomes have historically been unchanged. This study used data from the national Scientific Registry of Transplant Recipients (SRTR) and evaluated 1-year and 5-year graft survival and half-lives for kidney transplant recipients in the US. All adult (≥18 years) solitary kidney transplants (n = 331,216) from 1995 to 2017 were included in the analysis. Mean age was 49.4 years (SD +/-13.7), 60% male, and 25% Black. The overall (deceased and living donor) adjusted hazard of graft failure steadily decreased from 0.89 (95%CI: 0.88, 0.91) in era 2000–2004 to 0.46 (95%CI: 0.45, 0.47) for era 2014–2017 (1995–1999 as reference). Improvements in adjusted hazards of graft failure were more favorable for Blacks, diabetics and older recipients. Median survival for deceased donor transplants increased from 8.2 years in era 1995–1999 to an estimated 11.7 years in the most recent era. Living kidney donor transplant median survival increased from 12.1 years in 1995–1999 to an estimated 19.2 years for transplants in 2014–2017. In conclusion, these data show continuous improvement in long-term outcomes with more notable improvement among higher-risk subgroups, suggesting a narrowing in the gap for those disadvantaged after transplantation. 相似文献
994.
Jignesh K. Patel Guillaume Coutance Alexandre Loupy Deanna Dilibero Michele Hamilton Michelle Kittleson Evan Kransdorf Babak Azarbal Osamu Seguchi Xiaohai Zhang David Chang Dael Geft Lawrence Czer Shaida Varnous Jon A. Kobashigawa 《American journal of transplantation》2021,21(7):2479-2488
Allosensitization represents a major barrier to heart transplantation (HTx). We assessed the efficacy and safety of complement inhibition at transplant in highly sensitized heart transplant recipients. We performed a single-center, single-arm, open-label trial (NCT02013037). Patients with panel reactive antibodies (PRA) ≥70% and pre–formed donor-specific antibodies (DSA) were eligible. In addition to standard of care, patients received nine infusions of eculizumab during the first 2 months posttransplant. The primary composite endpoint was antibody-mediated rejection (AMR) ≥pAMR2 and/or left ventricular dysfunction during the first year. Secondary endpoints included hemodynamic compromise, allograft rejection, and patient survival. Twenty patients were included. Median cPRA and mean fluorescence intensity of immunodominant DSA were 95% (90%–97%) and 6250 (5000–10 000), respectively. Retrospective B cell and T cell flow crossmatches were positive in 14 and 11 patients, respectively. The primary endpoint occurred in four patients (20%). Survival at 1 year was 90% with no deaths resulting from AMR. In a prespecified analysis comparing treated patients to matched control patients, we observed a dramatic reduction in the risk of biopsy-proven AMR in patients treated with eculizumab (HR = 0.36, 95% CI = 0.14–0.95, p = .032). Our findings support the prophylactic use of complement inhibition for heart transplantation at high immunological risk. ClinincalTrials.gov, NCT02013037. 相似文献
995.
Laura N. Walti Catrina Mugglin Daniel Sidler Matteo Mombelli Oriol Manuel Hans H. Hirsch Nina Khanna Nicolas Mueller Christoph Berger Katia Boggian Christian Garzoni Dionysios Neofytos Christian van Delden Cédric Hirzel Swiss Transplant Cohort Study 《American journal of transplantation》2021,21(7):2532-2542
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation (SOT). Most PTLD cases are associated with Epstein–Barr virus (EBV) infection. The role of antiviral prophylaxis or rituximab therapy for prevention of PTLD in SOT recipients is controversial. In a nationwide cohort, we assessed the incidence, presentation, and outcome of histologically proven PTLD. We included 4765 patients with a follow-up duration of 23 807 person-years (py). Fifty-seven PTLD cases were identified; 39 (68%) were EBV positive (EBV+ PTLD). Incidence rates for EBV+ PTLD at 1, 2, and 3 years posttransplant were 3.51, 2.24, and 1.75/1000 py and 0.44, 0.25, and 0.29/1000 py for EBV− PTLD. We did not find an effect of antiviral prophylaxis on early and late EBV+ PTLD occurrence (early EBV+ PTLD: SHR 0.535 [95% CI 0.199–1.436], p = .264; late EBV+ PTLD: SHR 2.213, [95% CI 0.751–6.521], p = .150). However, none of the patients (0/191) who received a rituximab-containing induction treatment experienced PTLD, but 57 of 4574 patients without rituximab induction developed PTLD. In an adjusted restricted mean survival time model, PTLD-free survival was significantly longer (0.104 years [95% CI 0.077–0.131]) in patients receiving rituximab as induction treatment. This study provides novel data on the association of rituximab induction and reduced risk for PTLD. 相似文献
996.
Emilie Savoye Camille Legeai Julien Branchereau Samuel Gay Bruno Riou Francois Gaudez Benoit Veber Franck Bruyere Gaelle Cheisson Thomas Kerforne Lionel Badet Olivier Bastien Corinne Antoine and the cDCD National Steering Committee 《American journal of transplantation》2021,21(7):2424-2436
Controlled donation after circulatory death (cDCD) is used for “extended criteria” donors with poorer kidney transplant outcomes. The French cDCD program started in 2015 and is characterized by normothermic regional perfusion, hypothermic machine perfusion, and short cold ischemia time. We compared the outcomes of kidney transplantation from cDCD and brain-dead (DBD) donors, matching cDCD and DBD kidney transplants by propensity scoring for donor and recipient characteristics. The matching process retained 442 of 499 cDCD and 809 of 6185 DBD transplantations. The DGF rate was 20% in cDCD recipients compared with 28% in DBD recipients (adjusted relative risk [aRR], 1.43; 95% confidence interval [CI] 1.12–1.82). When DBD transplants were ranked by cold ischemia time and machine perfusion use and compared with cDCD transplants, the aRR of DGF was higher for DBD transplants without machine perfusion, regardless of the cold ischemia time (aRR with cold ischemia time <18 h, 1.57; 95% CI 1.20–2.03, vs aRR with cold ischemia time ≥18 h, 1.79; 95% CI 1.31–2.44). The 1-year graft survival rate was similar in both groups. Early outcome was better for kidney transplants from cDCD than from matched DBD transplants with this French protocol. 相似文献
997.
Nathalie Chavarot Gillian Divard Anne Scemla Lucile Amrouche Olivier Aubert Marianne Leruez-Ville Marc O. Timsit Claire Tinel Julien Zuber Christophe Legendre Dany Anglicheau Rebecca Sberro-Soussan 《American journal of transplantation》2021,21(7):2448-2458
Belatacept may increase cytomegalovirus (CMV) disease risk after conversion from CNI-based therapy. We analyzed CMV disease characteristics after belatacept conversion. Propensity score matching was used to compare CMV disease incidence in belatacept- and CNI-treated kidney transplant recipients (KTRs). CMV disease characteristics and risk factors under belatacept were analyzed. In total, 223 KTRs (median age [IQR] 59.2 years [45.4–68.5]) were converted to belatacept (median of 11.5 months [2.5–37.0] post-transplantation); 40/223 (17.9%) developed CMV disease. Independent risk factors included increased age (p = .0164), D+/R− CMV serostatus (p = .0220), and low eGFR at conversion (p = .0355). Among 181 belatacept-treated patients matched to 181 controls, 32/181 (17.7%) experienced CMV disease (vs. 5/181 controls [2.8%]). CMV disease cumulative incidences were 6.33 and 0.91/100 person-years (p-y) in belatacept and control groups, respectively. CMV disease risk was particularly high in elderly patients (converted >70 years) and those with eGFR <30 ml/min; cumulative incidences were 18.4 and 5.2/100 p-y, respectively. CMV diseases under belatacept were atypical, with late-onset disease (24/40 patients [60%]), high CMV seropositivity (27/40, 67%), increased severe and tissue-invasive disease rates (gastrointestinal involvement in 32/40 [80%]) and life-threatening diseases (4/40 [10%]). These findings should stimulate further research to secure the use of belatacept as a valuable rescue therapy in KTRs. 相似文献
998.
Benedict L. Phillips Maria Ibrahim George H. B. Greenhall Lisa Mumford Anthony Dorling Chris J. Callaghan 《American journal of transplantation》2021,21(10):3346-3355
Kidneys from donation after circulatory death (DCD) donors are utilized variably worldwide, in part due to high rates of delayed graft function (DGF) and putative associations with adverse longer-term outcomes. We aimed to determine whether the presence of DGF and its duration were associated with poor longer-term outcomes after kidney transplantation from DCD donors. Using the UK transplant registry, we identified 4714 kidney-only transplants from controlled DCD donors to adult recipients between 2006 and 2016; 2832 recipients (60·1%) had immediate graft function and 1882 (39·9%) had DGF. Of the 1847 recipients with DGF duration recorded, 926 (50·1%) had DGF < 7 days, 576 (31·2%) had DGF 7–14 days, and 345 (18·7%) had DGF >14 days. After risk adjustment, the presence of DGF was not associated with inferior long-term graft or patient survivals. However, DGF duration of >14 days was associated with an increased risk of death-censored graft failure (hazard ratio 1·7, p = ·001) and recipient death (hazard ratio 1·8, p < ·001) compared to grafts with immediate function. This study suggests that shorter periods of DGF have no adverse influence on graft or patient survival after DCD donor kidney transplantation and that DGF >14 days is a novel early biomarker for significantly worse longer-term outcomes. 相似文献
999.
Cedric Hirzel Arnaud G. L'Huillier Victor H. Ferreira Tina Marinelli Terrance Ku Matthew Ierullo Congrong Miao D. Scott Schmid Stephen Juvet Atul Humar Deepali Kumar 《American journal of transplantation》2021,21(6):2246-2253
Lung transplant recipients are at high risk for herpes zoster and preventive measures are a significant unmet need. We investigated the safety and immunogenicity of two doses of a recombinant zoster vaccine (RZV) in lung transplant recipients (≥50 years). We enrolled 50 patients of which 49 received at least one vaccine dose. Anti-glycoprotein E (gE) antibody levels (n = 43) increased significantly compared to baseline (median optical density [OD] 1.96; interquartile range [IQR]: 1.17–2.89) after the first (median OD 3.41, IQR 2.54–3.81, p < .0001) and second vaccine dose (median OD 3.63, IQR 3.39–3.86, p < .0001). gE-specific polyfunctional CD4+ T cell frequencies (n = 38) also increased from baseline (median 85 per 106 CD4+ T cells; IQR: 46–180) to the first (median 128 per 106 CD4+ T cells; IQR: 82–353; p = .023) and after the second dose (median 361 per 106 CD4+ T cells; IQR: 146–848; p < .0001). Tenderness (83.0%; 95%CI: 69.2–92.4%) and redness (31.9%; 95%CI: 19.1–47.1%) at injection site were common. One rejection episode within 3 weeks of vaccination was observed. This is the first study demonstrating that RZV was safe and elicited significant humoral and cell-mediated immunity in lung transplant recipients. RZV is a new option for the prevention of shingles in this population. 相似文献
1000.
Cecilia Nakid-Cordero Sylvain Choquet Nicolas Gauthier Noureddine Balegroune Nadine Tarantino Véronique Morel Nadia Arzouk Sonia Burrel Géraldine Rousseau Frédéric Charlotte Martin Larsen Vincent Vieillard Brigitte Autran Véronique Leblond Amélie Guihot for the K-VIROGREF Study Group 《American journal of transplantation》2021,21(8):2846-2863
EBV-positive and EBV-negative posttransplant lymphoproliferative disorders (PTLDs) arise in different immunovirological contexts and might have distinct pathophysiologies. To examine this hypothesis, we conducted a multicentric prospective study with 56 EBV-positive and 39 EBV-negative PTLD patients of the K-VIROGREF cohort, recruited at PTLD diagnosis and before treatment (2013–2019), and compared them to PTLD-free Transplant Controls (TC, n = 21). We measured absolute lymphocyte counts (n = 108), analyzed NK- and T cell phenotypes (n = 49 and 94), and performed EBV-specific functional assays (n = 16 and 42) by multiparameter flow cytometry and ELISpot-IFNγ assays (n = 50). EBV-negative PTLD patients, NK cells overexpressed Tim-3; the 2-year progression-free survival (PFS) was poorer in patients with a CD4 lymphopenia (CD4+<300 cells/mm3, p < .001). EBV-positive PTLD patients presented a profound NK-cell lymphopenia (median = 60 cells/mm3) and a high proportion of NK cells expressing PD-1 (vs. TC, p = .029) and apoptosis markers (vs. TC, p < .001). EBV-specific T cells of EBV-positive PTLD patients circulated in low proportions, showed immune exhaustion (p = .013 vs. TC) and poorly recognized the N-terminal portion of EBNA-3A viral protein. Altogether, this broad comparison of EBV-positive and EBV-negative PTLDs highlight distinct patterns of immunopathological mechanisms between these two diseases and provide new clues for immunotherapeutic strategies and PTLD prognosis. 相似文献